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Introduction previous operations. Duplex scan and angiography
showed occlusion of the common iliac artery, site of
Because chronic renal failure is a known risk factor for previous transplants, and mild atherosclerotic lesions
atherosclerosis and longer survival for haemodialysis in the infrainguinal vessels. The ankle–brachial index
patients has been reported,1 the occurrence of chronic was 0.3. The reconstruction did well for 30 months.
arterial disease and the need for peripheral arterial One month before re-admission he started a therapy
reconstruction are increasing in this group of patients.2 based on rHuEPO (3000 IU 3 times/week) because of
Human erythropoietin (rHuEPO) has been introduced moderate anaemia (red blood cell count=2.8·106/
to reverse the severe anaemia of end-stage renal dis- ll reference range: 3.9–5.5·106/ll – platelet count=
ease and to improve life quality of chronic uraemic 85·103/ll, reference range: 150–450·103/ll – haemo-
patients.3 globin=8.8 g/dl, reference range: 14.0–17.5 g/dl –
Several reports have recently focused on the risky haematocrit=27%, reference range: 41–50%). At pre-
side-effect of this therapy if haemoglobin concentration sentation he was afebrile, blood pressure was in the
is normalised to levels of 13.5–16.5 g/dl. An increased reference values. Laboratory tests showed a red blood
thrombogenicity of prosthetic arterial access for cell count of 4.26·106/ll, a haematocrit of 37.4%,
haemodialysis and an increase in cardiac-related fat- a haemoglobin of 10.8 g/dl, a platelets count of
alities are possible side-effects of this therapy.4–6 128·103/ll and a white blood cell count of 2.72 (ref-
erence range: 4.5–11.0·103/ll). Studies to assess the
coagulative profile (PT, PTT, fibrinogen and AT-III)
were within the reference range. The right lower limbCase Report
was cold and no distal pulses were palpable. A
thrombectomy of the occluded graft was successfullyA 53-year-old patient under recombinant human
carried out. No signs of infection or myointimal hyper-erythropoietin (rHuEPO) had recurrent thrombosis of
plasia were observed. Postoperatively all distal pulsesan axillofemoral bypass graft. In 1981, he made two
unsuccessful kidney transplants for chronic glo- were present and the ankle–brachial index was 0.8. The
merulonephritis that resulted in end-stage renal fail- postoperative course was complicated by an episode of
ure. Thereafter, he started chronic haemodialysis on a angina pectoris. rHuEPO therapy was continued at
3-day basis. In 1995, he underwent a right axillofemoral the same dosage. One month after discharge the patient
bypass graft (externally supported Dacron, 8 mm in was re-admitted for critical ischaemia of the right
diameter) for critical ischaemia. An abdominal upper and lower limbs. The bypass was occluded
procedure was contraindicated because of multiple and the ispilateral upper and lower limb pulses were
absent. Laboratory tests were comparable to those
of the last admission. An emergency operation was
* Please address all correspondence to: A. Mingoli, First Department planned, but the patient had a fatal myocardial in-of Surgery, Policlinico Umberto Io, Viale del Policlinico 155, 00161
Rome, Italy. farction.
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Discussion with anaemia and the potential risk for peripheral
arterial reconstruction thrombosis should be achieved,
either by reducing the dosage of rHuEPO or with theThe benefits of rHuEPO therapy are widely accepted,
association of an anticoagulant drug.but the present case elucidates some of the risks. Since
rHuEPO was introduced, a great debate was present
in the literature concerning the possible thrombogenic
Referencesside-effects of rHuEPO therapy. At present an in-
creased thrombogenicity of vascular prosthetic arterial
1 Wheeler DC. Cardiovascular disease in patients with chronic
access for haemodialysis, if haemoglobin levels are renal failure. Lancet 1996; 348: 1673–1674.
2 Isiklar MH, Kulbaski M, MacDonald MJ, Lumsden AB. Infra-normalised, was observed.4 Furthermore, an increase
inguinal bypass in end-stage renal disease: when is it justified?in cardiac-related fatalities in patients under rHuEPO
Semin Vasc Surg 1997; 10: 42–48.
therapy was noted5 and a recent, large, controlled 3 Moreno F, Aracil FJ, Perez R, Valderrabano F. Controlled
study on the improvement of quality of life in elderly hemodialysisstudy stated that in patients with clinically evident
patients after correcting end-stage renal disease-related anemiacongestive heart failure or ischaemic heart disease, with erythropoietin. Am J Kidney Dis 1996; 27: 548–556.
administration of rHuEPO to raise haematocrit to 42% 4 Churchill DN, Muirhead N, Goldstein M et al. Probability of
thrombosis of vascular access among hemodialysis patientsis not recommended.6 No data are available on peri-
treated with recombinant human erythropoietin. J Am Soc Nephrolpheral arterial reconstruction. 1994; 4: 1809–1813.
Our case demonstrates that peripheral arterial grafts 5 Iseki K, Nishime K, Uehara H et al. Increased risk of cardio-
vascular disease with erythropoietin in chronic dialysis patients.may undergo an increased risk of thrombosis in
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patients under rHuEPO therapy. However, we should 6 Besarab A, Bolton WK, Browne JK et al. The effects of normal
as compared with low hematocrit values in patients with cardiacconsider that intradialytic hypovolaemia, hypotension
disease who are receiving hemodialysis. N Engl J Med 1998; 339:or a decreased cardiac output might have also con-
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tributed to graft thrombosis. In conclusion, a balance
between rHuEPO therapy of haemodialysis patients Accepted 12 March 1999
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